We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-48.00 | -0.44% | 10,866.00 | 10,866.00 | 10,870.00 | 10,934.00 | 10,764.00 | 10,914.00 | 457,934 | 14:34:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 28.22 | 168.07B |
By Kyle Morris
AstraZeneca PLC said Monday that Enhertu has been recommended for approval in the European Union for patients with gastric cancer.
The Anglo-Swedish pharma major said Enhertu--trastuzumab deruxtecan--has been recommended in the EU by the European Medicines Agency as monotherapy for the treatment of patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
November 14, 2022 02:37 ET (07:37 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions